MyAlcon for Professionals Logo
MyAlcon for Consumer

MyAlcon | Caribbean

This page is available in English. Select below for other countries.

Select Another Country

Shockingly Brilliant Distance Vision, Time After Time1-5

 

Clareon® Monofocal IOLs give your patients functional intermediate vision while maintaining exceptional sharp, crisp distance vision.6-9 But what they see might surprise them.

Shockingly Brilliant Distance Vision, Time After Time1-5

Clareon® Monofocal IOLs give your patients functional intermediate vision while maintaining exceptional sharp, crisp distance vision.6-9 But what they see might surprise them.

Clareon® Delivers Clear, Predictable Performance1-3,10,11*†

  • Excellent Quality of Vision with Predictable Functional Intermediate3,12,13
  • Maximum Refractive Predictability3,5,14
  • Excellent Clarity10*†
3-dimensional image of a yellow Clareon Monofocal IOL.

*Compared in vitro with TECNIS‡ OptiBlue‡ ZCB00V, TECNIS‡ ZCB00, Vivinex‡ XY-1, Eternity‡ Natural Uni W-60 and enVista‡ MX60. (Surface haze and SSNGs: n=10 lenses per group, P<0.001; Glistenings: n=30 IOLs per group, P<0.001).

†Among the lowest levels of surface haze, SSNGs, and glistenings of competitive IOLs.

‡Trademarks are the property of their respective owners.

Excellent quality of vision with predictable functional intermediate3,6-8,12,13,15

Clareon® IOL delivers functional intermediate vision up to 20/32 at 66 cm while maintaining 20/20 vision at distance6-8,15*†

A blue-coloured chart depicting the results of two Vivity registration studies using the AcrySof IQ monofocal IOL as a control. Callouts depict the percentage of patients achieving functional IVA; 83% of patients achieve UCIVA of ≥20/32 and 74% of patients achieve DCIVA of ≥20/32.

*Based on two Vivity® registration studies, which used SN60WF as the control, AcrySof® IQ monofocal IOLs provided mean binocular distance corrected intermediate VA at 0.2 logMAR
†Based on Studies with AcrySof®; Clareon® and AcrySof® are optically equivalent with the same -0.2µm aspheric design resulting in improved depth of focus. UCIVA = Uncorrected Intermediate Visual Acuity DCIVA = Distance Corrected Intermediate Visual Acuity OUS = Outside United States

Clareon® proprietary edge curvature significantly reduces edge glare3,12,13

An internal image of an eye implanted with the Clareon IOL over a black background. As light enters the eyes, the visual depicts significantly reduced reflected glare in vitro. An image in another bubble highlights the edge design of the Clareon IOL.

 

Clareon® IOL Precision Edge Design

An internal image of an eye implanted with straight edge IOL over a black background. As light enters the eyes, the visual depicts significantly more reflected glare in vitro. An image in another bubble highlights the precision edge design of a straight edge IOL.

 

Straight Edge IOL

*Evaluated in a schematic model eye and in vitro evaluation of positive dysphotopsia or glare types photic phenomena. Optical ray trace simulations of incoming light were generated based on a collimated light source with a wavelength of 550 nm for various off-axis angles of illumination (n=5 IOLs per group, +25.0 D). The simulation analyses were verified using a laboratory glare bench-top measurement system, whereby glare components formed from off-axis illumination of IOLs fitted into an artificial eye model were measured. Only clinical studies can confirm whether the differences observed between the IOLs in vitro are clinically significant.

Visualize how glare can impact everyday life with this glare simulation

Clareon® features a fully usable 6 mm aspheric optic dedicated to sharp, crisp vision3,12,13

Close-up image of the Clareon IOL with letters behind it, showing the full use of the 6 mm aspheric optic.
Close-up image of the Clareon IOL with letters behind it, showing the full use of the 6 mm aspheric optic.
Clareon®

 

Fully usable 6 mm aspheric optic

Close-up image of a TECNIS 1-Piece IOL with letters behind it, showing the use of the limited 4.9 mm aspheric optic.
Close-up image of a TECNIS 1-Piece IOL with letters behind it, showing the use of the limited 4.9 mm aspheric optic.
TECNIS* 1-Piece

 

Usable aspheric optic limited to 4.9 mm

Close-up image of an enVista IOL with letters behind it, showing the use of the limited 4.9 mm aspheric optic.
Close-up image of an enVista IOL with letters behind it, showing the use of the limited 4.9 mm aspheric optic.
enVista*

 

Usable aspheric optic limited to 4.9 mm

Compared with TECNIS* 1-Piece and enVista* IOL in an in vitro study. Images were captured using a Keyence video microscope under precisely controlled conditions. Each IOL (+25.0 D) was placed into a wet cell model eye containing BSS® and a spherical aberration neutral simulated cornea. For each IOL, the target image was captured using the identical test conditions and camera settings without additional focusing. All elements (the Keyence microscope, the IOL in wet cell, the model cornea, and the target image) were located in exactly the same place using the exact same imaging settings on the Keyence in the manual mode. Optics are presented in black and white for illustrative purposes only.

*Trademarks are the property of their respective owners.

Clareon® Guards Against PCO for Long-term ​Visual Quality3,16​

A circular visual of a microscopic image of the Clareon IOL with a teal-coloured line highlighting the continuous posterior barrier. Two circular callouts also appear. The first callout over a teal-coloured background states that the Clareon IOL achieves an Nd:YAG rate of 1.5% at 1 year. The second callout, over a grey background, states that the AcrySof IQ IOL achieves an Nd:YAG rate of 2.2% at 1 year.

Continuous Posterior Barrier and Low Nd:YAG Rates

Maximum Refractive Predictability3-5,14

 

STABLEFORCE® Haptics help Clareon® deliver superior axial stability compared to other IOLs3-5,14*†

Variations in the capsular bag size and IOL haptic design lead to IOL axial displacement that can result in residual refractive errors.4

An image of the Clareon IOL from the side, depicting the shape of the IOL when uncompressed. An image of the Clareon IOL from the side, depicting the shape of the IOL with 9 mm compression.

*Compared in vitro with enVista† MX60, TECNIS† ZCB00, and Vivinex† XY-1 (n=10 lenses per group, P<0.05).

†Axial displacement results as a function of compression diameter with corresponding simulated dioptric power shift at the corneal plane in vitro.

Clareon® delivers consistent centration across capsule sizes3,5,14*

 

STABLEFORCE® Haptics provide excellent centration and stability for a range of capsule sizes.3,5,14

Five illustrations of the Clareon IOL of different capsule size: 11, 10.5, 10, 9.5 and 9 mm.
Five illustrations of the Clareon IOL of different capsule size: 11, 10.5, 10, 9.5 and 9 mm.

For illustrative purposes only.

*Compared in vitro with enVista† MX60, TECNIS† ZCB00, and Vivinex† XY-1 (n=10 lenses per group, P<0.05).

†Trademarks are the property of their respective owners.

Advanced Manufacturing Process Delivers Unsurpassed Clarity2,10,18,19

Clareon® offers long lasting, glistening-free results2,11*

 

In long-term clinical studies, Clareon® IOLs were reported as glistening-free over 3 and 9 years.2,11*†

This image is a photograph of a patient’s eye at 9 years following the implantation of a Clareon IOL.

*Defined as Miyata grade 0, <25mv/mm2 over 3 years (n=138), and over 9 years (n=20), respectively.

†Compared in vitro with TECNIS‡ OptiBlue‡ ZCB00V, TECNIS‡ ZCB00, Vivinex‡ XY-1, Eternity‡ Natural Uni W-60, and enVista‡ MX60. (Surface haze and SSNGs: n=10 lenses per group, P<0.001; glistenings: n=30 IOLs per group, P<0.001.)

‡Trademarks are the property of their respective owners.

Significantly Less Glistenings Than Other IOLs10

 

In an in vitro study, Clareon® IOL demonstrated lower levels of glistenings compared with TECNIS† and Vivinex† IOLs.10‡

A bar graph depicting the glistening density in vitro of the Clareon IOL against 3 competitor IOLS: the Vivinex XY-1, the TECNIS 1-Piece and the TECNIS OptiBlue IOLs. Double-dagger symbols above the three competitor IOL bar graphs denote that a statistical significance a determined compared with Clareon.

*Compared in vitro with TECNIS† OptiBlue† ZCB00V, TECNIS† ZCB00, Vivinex† XY-1, Eternity† Natural Uni W-60, and enVista† MX60. (Surface haze and SSNGs: n=10 lenses per group, P<0.001; glistenings: n=30 IOLs per group, P<0.001.)
†Trademarks are the property of their respective owners.
‡Denotes statistical significance for comparison of slit lamp surface haze as determined by a one-way ANOVA (P<0.001) compared with Clareon®.

A Rotationally Stable IOL with an Advanced Precision Edge Design and Unsurpassed Clarity5,10,13,20,21

 
Two illustrations of Clareon Toric IOLs. “Ninety-five percent” appears in the first illustration, indicating that 95% of Clareon IOLs had an absolute rotation of ≤5 degrees on Day 1. “Two degrees” appears in the second illustration, indicating that 2 degrees was the mean rotation of Clareon IOLs from baseline at 6 months post-op.

*In an additional analysis, 98.4% of Clareon® IOLs had an absolute rotation of ≤10° between surgery and 6 months.


†Baseline is defined as ≤1-hour post-surgery in a randomized controlled trial (N=141).

Alcon Online Toric IOL Calculator features the Barrett Toric and Holladay Total SIA Toric Algorithms

Launch Alcon Toric Calculator
An image of an open laptop with the Alcon Online Toric IOL Calculator featured on the screen.

Available in manual and preloaded delivery devices, specifically designed for the Clareon® platform

 

Please contact your local Alcon representative for IOL delivery systems
available in your market.

Available in manual and preloaded delivery devices, specifically designed for the Clareon® platform

 

Please contact your local Alcon representative for IOL delivery systems available in your market.

 

Clareon® and Clareon® Toric Clinical Studies

Goto S, Maeda N, Ohnuma K, & Noda T. Comparison of two one-piece acrylic foldable intraocular lenses: Short-term change in axial movement after cataract surgery and its effect on refraction

 

Comparing the change in intraocular lens (IOL) axial movement, corneal power, and postoperative refraction of eyes implanted with two different single-piece, open loop, acrylic foldable IOLs with planar-haptic design

Lehmann R, Maxwell A, Lubeck DM, et al. Effectiveness and safety of the Clareon® monofocal intraocular lens: Outcomes from a 12-month single-arm clinical study in a large sample

 

Assessing the effectiveness and safety of the novel Clareon® intraocular lens

Von Tress M, Marotta JS, Lane SS, & Sarangapani R. A meta-analysis of Nd:YAG capsulotomy rates for two hydrophobic intraocular lens materials

 

Estimating and comparing Nd:YAG capsulotomy rates for AcrySof® and Clareon® intraocular lens materials using historical data from the medical literature and Alcon-sponsored clinical studies

Walters TR, Lehmann R, Moyes A, et al. Rotational stability of the Clareon® monofocal aspheric hydrophobic acrylic intraocular lens 6 months after implantation

 

Determining the rotational stability of the Clareon® aspheric, monofocal, intraocular lens (IOL) up to 6 months after implantation

Technical Specifications

Table of specifications for Clareon Family of IOLs
Table of specifications for Clareon® Monofocal IOL

†Blue Light + UV Filter

‡UV Filter Only

Table of specifications for Clareon Toric IOL

*Based on an average pseudophakic human eye using an SRK/T optical A-constant of 119.1

†Blue Light + UV Filter

‡UV Filter Only

Instructions for Use (IFU)

 

For a full list of indications, contraindications and warnings, please visit ifu.alcon.com and refer to the relevant product’s instructions for use.

Visit IFU Database

Alcon Experience Academy

 

For relevant training content from industry thought leaders

Visit AEA Portal

References:

1. Lehmann R, Maxwell A, Lubeck DM, Fong R, Walters TR, Fakadej A. Effectiveness and Safety of the Clareon Monofocal Intraocular Lens: Outcomes from a 12-Month Single-Arm Clinical Study in a Large Sample. Clin Ophthalmol. 2021;15:1647-1657. Published 2021 Apr 20. doi:10.2147/OPTH.S295008​.

2. Oshika T, Fujita Y, Inamura M, Miyata K. Mid-term and long-term clinical assessments of a new 1-piece hydrophobic acrylic IOL with hydroxyethyl methacrylate. ​J Cataract Refract Surg. 2020;46(5):682-687.​

3. Clareon® IOL Directions for Use.​

4. Lane, S, Collins, S, Das, K et al. Evaluation of intraocular lens mechanical stability. J Cataract Refract Surg. 2019;45(4):501-506.​

5. Alcon Data on File, 2017. [TDOC-0054028]​.

6. AcrySof® IQ Vivity™ IOL Directions for Use​.

7. Bala C, Poyales F, Guarro M, Mesa RR, Mearza A, Varma DK, Jasti S, Lemp-Hull J. Multi-country clinical outcomes of a new nondiffractive presbyopia-correcting intraocular lens. J Cataract Refract Surg. 2021 Jun 11. doi: 10.1097/j.jcrs.0000000000000712. Epub ahead of print. PMID: 34288635.​

8. Alcon Data on File, 2021. [A01970-REP-211731]​.

9. Varma, Devesh, et al. Clinical Outcomes of a New Non-Diffractive Presbyopia-Correcting Intraocular Lens From Two Large Confirmatory Studies. American Academy of Ophthalmology. Abstract: PA005.

10. Werner L, Thatthamla I, Ong M, et al. Evaluation of clarity characteristics in a new hydrophobic acrylic IOL in comparison to commercially available IOLs. J Cataract Refract Surg. 2019;45(10):1490-1497. doi:10.1016/j.jcrs.2019.05.017​.

11. Maxwell A, Suryakumar R. Long-term effectiveness and safety of a three-piece acrylic hydrophobic intraocular lens modified with hydroxyethyl-methacrylate: an open-label, 3-year follow-up study. Clin Ophthalmol. 2018;12:2031–2037.​

12. Alcon Data on File, 2017. [TDOC-0050244].

13. Das KK, Werner L, Collins S, Hong X. In vitro and schematic model eye assessment of glare or positive dysphotopsia-type photic phenomena: Comparison of a new material IOL to other monofocal IOLs. J Cataract Refract Surg. 2019;45(2):219-227.​

14. Alcon Data on File, 2017. [TDOC-0053564]​.

15. Alcon Data on File; TDOC – 055575; 09/Apr/2019​.

16. AcrySof® IQ IOL Directions for Use.

17. Alcon Data on File, 2017. [TDOC-0054422]​.

18. Alcon Data on File, 2020. [TDOC-0057291]​.

19. Stanojcic N, O’Brart D, Hull C, et al. Visual and refractive outcomes and glistenings occurrence after implantation of 2 hydrophobic acrylic aspheric monofocal IOLs. J Cataract Refract Surg. 2020;46(7):986-994.​

20. Lee BS, Chang DF. Comparison of the rotational stability of two toric intraocular lenses in 1273 consecutive eyes. Ophthalmology. 2018;125(9):1325-1331​.

21. Clareon® Toric IOL Directions for Use.​

22. Alcon Data on File, 2019. [TDOC-0055470]​.

 

Please refer to the relevant product direction for use for list of indications, contraindications and warnings. Find at: https://ifu.alcon.com 

“Exclusive Use For Health Care Professionals”

© 2024 Alcon Inc. CAR-CLM-2400003